Inventor
Pingda Ren
Inventor
San Diego, CA, US
Overview
Patents· 108 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes21%
Y02ATechnologies for adaptation to climate change6%
C07BGeneral methods of organic chemistry3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
A61NElectrotherapy2%
Y02PClimate change mitigation technologies in the production or processing of goods2%
C12NMicroorganisms or enzymes2%
PatentTitleYear
11,098,083Peptide that regulates fat metabolism and method for regulating fat metabolism202110,975,071Inhibitors of KRAS G12C mutant proteins202110,927,125Substituted cinnolines as inhibitors of KRAS G12C202110,919,850Covalent inhibitors of KRas G12C202110,882,847Inhibitors of KRAS G12C mutant proteins202110,875,842Inhibitors of KRAS G12C mutant proteins202010,858,343Inhibitors of KRAS G12C mutant proteins202010,829,458Substituted quinazoline compounds and methods of use thereof202010,822,312Substituted quinazoline compounds and methods of use202010,781,218Substituted inhibitors of menin-MLL and methods of use202010,752,639Bridged bicyclic inhibitors of menin-MLL and methods of use202010,745,385Covalent inhibitors of KRAS202010,736,897Compounds and methods of use thereof for treatment of cancer202010,730,867Inhibitors of KRAS G12C mutant proteins202010,723,738Inhibitors of KRAS G12C mutant proteins202010,689,356Inhibitors of KRAS G12C mutant proteins202010,647,703Inhibitors of KRAS G12C mutant proteins202010,646,488Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof202010,588,907Methods and compositions for inhibiting the interaction of menin with MLL proteins202010,550,122Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof202010,428,064Fused-tricyclic inhibitors of KRAS and methods of use thereof201910,414,7572-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof201910,377,743Inhibitors of RAS and methods of use thereof201910,370,386Substituted quinolines as inhibitors of KRAS G12C201910,351,550Substituted quinazoline compounds and methods of use thereof201910,301,317Inhibitors of ERK and methods of use201910,280,172Inhibitors of KRAS G12C mutant proteins201910,273,207Covalent inhibitors of kras G12C201910,246,424Substituted quinazoline compounds and methods of use thereof201910,246,464Thienopyrimidine and thienopyridine compounds and methods of use thereof201910,174,041Methods and compositions for inhibiting the interaction of menin with MLL proteins201910,172,858Combination pharmaceutical compositions and uses thereof201910,144,724Substituted quinazoline compounds and methods of use thereof201810,111,874Combination therapies for treatment of cancer201810,077,271Methods and compositions for inhibiting the interaction of menin with MLL proteins201810,011,600Methods and compositions for inhibition of Ras20189,988,357Methods for preparation of quinazoline derivatives20189,951,078Inhibitors of ERK and methods of use20189,926,267'Covalent inhibitors of K-Ras G12C'20189,862,701'Inhibitors of KRAS G12C mutant proteins'20189,840,505'Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof'20179,840,516'Substituted quinazolines as inhibitors of KRAS G12C'2017RE046621Processes for preparing isoquinolinones and solid forms of isoquinolinones20179,828,378Kinase inhibitors and methods of use20179,822,131'Certain chemical entities, compositions and methods'20179,810,690'Method for screening inhibitors of Ras'20179,790,228'Heterocyclic kinase inhibitors'20179,745,319'Irreversible covalent inhibitors of the GTPase K-Ras G12C'20179,738,644'Chemical compounds, compositions and methods for kinase modulation'20179,718,815'Heterocyclic compounds and uses thereof'20179,682,141'Combination of kinase inhibitors and uses thereof'20179,655,892'Certain chemical entities, compositions and methods'20179,637,492'Benzothiazole kinase inhibitors and methods of use'20179,629,843'MTOR modulators and uses thereof'20179,624,228'Inhibitors of ERK and methods of use'20179,605,003'Heterocyclic compounds and uses thereof'20179,546,180'Heterocyclic compounds and uses thereof'20179,522,146'Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20169,403,820'Kinase inhibitor polymorphs'20169,388,183'Heterocyclic compounds and uses thereof'20169,359,352'Substituted benzimidazoles as PI3 kinase inhibitors'20169,359,349'Substituted quinazolines as kinase inhibitors'20169,345,706'Benzoxazole kinase inhibitors and methods of use'20169,315,505'Heterocyclic compounds and uses thereof'20169,295,673'Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof'20169,296,742'Heterocyclic kinase inhibitors'20169,290,497'Processes for preparing isoquinolinones and solid forms of isoquinolinones'20169,255,108'Heterocyclic compounds and uses thereof'20169,227,978'Covalent inhibitors of Kras G12C'20169,216,982'Certain chemical entities, compositions and methods'20159,206,182'Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20159,181,221'Chemical compounds, compositions and methods for kinase modulation'20159,127,000'Heterocyclic compounds and uses thereof'20159,115,141'Substituted isoquinolinones and methods of treatment thereof'20159,096,590'Substituted benzoxazoles as PI3 kinase inhibitors'20159,096,611'Kinase inhibitors and methods of use'20159,085,560'Heterocyclic compounds and uses thereof'20159,056,877'Heterocyclic compounds and uses thereof'20158,993,580'Benzothiazole kinase inhibitors and methods of use'20158,969,363'Heterocyclic compounds and uses thereof'20158,940,742'Heterocyclic compounds and uses thereof'20158,901,133'Heterocyclic compounds and uses thereof'20148,809,349'Processes for preparing isoquinolinones and solid forms of isoquinolinones'20148,785,454'Heterocyclic compounds and uses thereof'20148,785,470'Heterocyclic compounds and uses thereof'20148,785,456'Substituted isoquinolin-1(2H)-ones, and methods of use thereof'20148,703,777'Certain chemical entities, compositions and methods'20148,703,778'Heterocyclic kinase inhibitors'20148,637,542'Kinase inhibitors and methods of use'20148,604,032'Chemical compounds, compositions and methods for kinase modulation'20138,569,323'Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof'20138,476,282'Benzoxazole kinase inhibitors and methods of use'20138,476,431'Benzoxazole kinase inhibitors and methods of use'20138,450,329'Benzoxazole kinase inhibitors and methods of use'20138,450,480'Benzoxazole kinase inhibitors and methods of use'20138,426,404'Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors'20138,202,876'Compounds and compositions as protein kinase inhibitors'20128,193,182'Substituted isoquinolin-1(2H)-ones, and methods of use thereof'20128,183,248'Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors'20128,026,243'[4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors'20117,846,923'Compounds and compositions as protein kinase inhbitors'20107,745,437'Compounds and compositions as protein kinase inhibitors'20107,678,792'Compositions and methods for modulating c-kit and PDGFR receptors'20107,642,255'Compounds and compositions as protein kinase inhibitors'20107,589,101'Compounds and compositions as protein kinase inhibitors'20097,423,038'Compounds and compositions as protein kinase inhibitors'20087,371,750'Compounds and compositions as protein kinase inhibitors'20087,151,096'Cyclic compounds and compositions as protein kinase inhibitors'2006Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2006–2021Based in San Diego, CA, US· patent location history
2011Based in Emeryville, CA, US· patent location history
2012–2016Patents assigned to REN PINGDA (24)· patent assignee history
2012–2016Patents assigned to LIU YI (21)· patent assignee history
2013–2019Patents assigned to INTELLIKINE LLC (28)· patent assignee history
2013–2020Patents assigned to INFINITY PHARMACEUTICALS INC (19)· patent assignee history
2016–2021Patents assigned to ARAXES PHARMA LLC (33)· patent assignee history
2018–2020Based in San Bernardino, CA, US· patent location history
2019Based in La Jolla, CA, US· patent location history
2021Based in Shenzhen, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARAXES PHARMA LLC | 33 | 2016–2021 |
| INTELLIKINE LLC | 28 | 2013–2019 |
| REN PINGDAself | 24 | 2012–2016 |
| LIU YI | 21 | 2012–2016 |
| INFINITY PHARMACEUTICALS INC | 19 | 2013–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 103 | 2006–2021 |
| San Bernardino, California, US | 2 | 2018–2020 |
| Shenzhen, CN | 1 | 2021 |
| La Jolla, California, US | 1 | 2019 |
| Emeryville, California, US | 1 | 2011 |